MCK · 10-Q · 2026Q2 · Full report

Headcount and Restructuring

MCKESSON CORP · 2026-08-05 · Importance 40 · Surprise 42 · From source text

During the first quarter of fiscal 2027, McKesson approved multi-year Corporate initiatives involving organizational changes, process enhancements, and automation solutions to improve efficiency and productivity. The fiscal 2027 program is expected to be substantially complete by the end of fiscal 2028 and consists primarily of severance, employee-related, and exit-related costs. A separate Prescription Technology Solutions initiative includes headcount reductions, facility exits or downsizing, and other cost-optimization actions, with completion expected by the end of fiscal 2029. The filing also reports ongoing fiscal 2025 enterprise-wide technology-service modernization initiatives across Corporate, Medical-Surgical Solutions, and North American Pharmaceutical, expected to be substantially complete in fiscal 2028.

Key facts

• During the first quarter of fiscal 2027, McKesson approved multi-year Corporate initiatives and anticipates total charges of approximately $230 million to $310 million, consisting primarily of severance and employee-related costs and exit-related costs; programs expected to be substantially complete by the end of fiscal 2028. source
• An initiative within Prescription Technology Solutions approved in the fourth quarter of fiscal 2026 anticipates total charges between $200 million and $250 million, McKesson recorded charges of $61 million in the first quarter of fiscal 2027; program anticipated to be substantially complete by the end of fiscal 2029. source
• Enterprise-wide technology initiatives approved in the second quarter of fiscal 2025 anticipate total charges of $650 million to $700 million and are anticipated to be substantially complete in fiscal 2028; McKesson recorded charges of $45 million and $38 million for the three months ended June 30, 2026 and 2025, respectively, related to these initiatives. source
• Corporate expenses, net included restructuring charges of $ million and $ million for the three months ended June 30, 2026 and 2025, respectively (amounts redacted), a credit of $ million related to estimated liability for opioid related claims for three months ended June 30, 2026, and charges of $ million related to planned separation of Medical-Surgical Solutions for three months ended June 30, 2026 (all amounts redacted). source
• Other segment expense, net for Prescription Technology Solutions includes charges of $61 million for the three months ended June 30, 2026 for restructuring initiatives. source
• Prescription Technology Solutions other segment expense included restructuring charges of $ million for three months ended June 30, 2026. source
• Restructuring, impairment, and related charges, net were $136 million for the three months ended June 30, 2026 and $47 million for the three months ended June 30, 2025. source

Impact estimates